Dianthus Therapeutics, Inc. (DNTH) stock analysis
In our weekly check, Dianthus Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 3, red flags: 12.
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as DNTH.
What our checks show for DNTH
Red flags
- The net margin fell by 576 points over 5 years, to -1464%: the company keeps less of each sale as profit.
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Weak EPS forecast
- Revenue fell 24.9% a year over the last 3 years.
- The company is losing money.
- Free cash flow is negative: the business spends more cash than it brings in.
- The price is 3060 times earnings (P/E): the market already pays for a lot of future growth.
- The price swings a lot: 57.1% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 98% from a peak. Would you have held through that?
- The share count grew by 633% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- The gross margin fell by 2.8 points, to 97.2%: costs are rising faster than prices.
- Earnings per share fell 84.2% a year over the last 3 years.
- The stock is still below its previous peak.
Strengths
- Debt is low: 0x equity.
- Analysts expect revenue to grow about 107% a year over the next years.
- Analysts expect the net margin to improve by 208 points from today's -1464%.
- Beta 0.08: the stock usually moves less than the market.
Similar companies
SRRK · PTCT · COGT · EWTX · MANE · ERAS
Questions
What grade does Dianthus Therapeutics, Inc. (DNTH) have?
In our weekly check, Dianthus Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 3, red flags: 12. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of DNTH stock?
This week's biggest flags for Dianthus Therapeutics, Inc.: Margins falling, Profits not backed by cash, Weak EPS forecast. In total 15 of 22 checks show a warning or a red flag.
What does Dianthus Therapeutics, Inc. do?
Dianthus Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as DNTH.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis